Ohcanbohtosat - Matthias Jeschke

  • Čájehuvvo 1 - 2 / 2
Aiddostahte ozu
  1. 1
    Evaluation of Inflammatory Markers as Prognostic Factors in the Treatment of Hepatocellular Carcinoma (HCC) with Degradable Starch Microspheres by Transarterial Chemoembolization (DSM-TACE)

    Evaluation of Inflammatory Markers as Prognostic Factors in the Treatment of Hepatocellular Carcinoma (HCC) with Degradable Starch Microspheres by Transarterial Chemoembolization (... Dahkki Hannah L Steinberg‐Vorhoff, Andriana Tropotel, Jens Theysohn, Benedikt M. Schaarschmidt, Johannes Haubold, Matthias Jeschke, Leonie Jochheim, Johannes Ludwig

    Almmustuhtton 2025
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  2. 2
    Atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma with impaired liver function and prior systemic therapy: a real-world experience

    Atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma with impaired liver function and prior systemic therapy: a real-world experience Dahkki Tiago B. R. Castro, Leonie Jochheim, Melanie Bathon, Sabrina Welland, Bernhard Scheiner, Kateryna Shmanko, Daniel Roessler, Najib Ben Khaled, Matthias Jeschke, Johannes Ludwig, Jens U. Marquardt, Arndt Weinmann, Matthias Pinter, Christian M. Lange, Arndt Vogel, Anna Saborowski

    Almmustuhtton 2022
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:

Ohcanreaiddut: